Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Receivables (2024 - 2025)

Syndax Pharmaceuticals (SNDX) has 2 years of Change in Receivables data on record, last reported at -$11.4 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 249.5% year-over-year to -$11.4 million; the TTM value through Dec 2025 reached $6.4 million, down 15.34%, while the annual FY2025 figure was $6.4 million, 15.34% down from the prior year.
  • Change in Receivables reached -$11.4 million in Q4 2025 per SNDX's latest filing, down from $5.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $11.9 million in Q2 2025 and bottomed at -$11.4 million in Q4 2025.